Usefulness of contrast-enhanced ultrasound (CEUS) in Crohn’s disease pediatric patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0005685

Enrollment

Registered

2020-12-21

Start date

2020-12-01

Completion date

Unknown

Last updated

2021-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : We injected the second generation, ultrasonic contrast agent (SonoVue, Bracco, Milan, Italy) as a bolus of 0.03 ml/kg through a three-way 20-gauge catheter in an antecubital vein, followed by a

NaCl)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are under the age of 18 with Crohn’s disease with colonoscopy within 2 years of IRB approval

Exclusion criteria

Exclusion criteria: Patients who are over the age of 18 and under the age of two - Patients who did not under go colonoscopy - Patients who have other bowel disease or mass than Crohn’s disease - High allergic sensitivity to Sonovue injection agent or sulfur hexafluoride - Patients who have right to left shunt, pulmonary hypertension, or systemic hypertension - Patients who have end stage renal or liver disease or septic shock

Design outcomes

Secondary

Measure	Time frame
Check if contrast enhancement ultrasound can find lesions based on endoscopy.;Significant quantitative contrast enhancement ultrasonic parameters reflecting treatment	—

Primary

Measure	Time frame
feasibility of Contrast Enhanced Ultrasound (CEUS) in the assessment of Crohn’s disease (CD) without major adverse effect	—

Countries

Korea, Republic of

Contacts

Public ContactHeasung Yoon

Yonsei University Health System, Severance Hospital

Outcome results